A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: The PrOP study

Journal of Bone and Mineral Research

Volumn 28, Issue 11, 2013, Pages 2266-2276

  Horwitz, Mara J ^a   Augustine, Marilyn ^a   Kahn, Leila ^a   Martin, Emily ^a   Oakley, Christine C ^a   Carneiro, Raquel M ^a   Tedesco, Mary Beth ^a   Laslavic, Angela ^a   Sereika, Susan M ^b   Bisello, Alessandro ^a   Garcia Ocaña, Adolfo ^a,c   Gundberg, Caren M ^d   Cauley, Jane A ^b   Stewart, Andrew F ^a,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ANABOLIC; BONE TURNOVER; DXA; OSTEOPOROSIS; PTH; PTHrP

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CALCITRIOL; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE RELATED PROTEIN[1-36]; PARATHYROID HORMONE[1-34]; PROCOLLAGEN; PROCOLLAGEN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; HIP; HUMAN; HYPERCALCEMIA; LUMBAR SPINE; MAJOR CLINICAL STUDY; OPTIMAL DRUG DOSE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ANABOLIC; BONE TURNOVER; DXA; OSTEOPOROSIS; PTH; PTHRP;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; DEMOGRAPHY; FEMALE; HUMANS; MIDDLE AGED; MINERALS; PARATHYROID HORMONE; PARATHYROID HORMONE-RELATED PROTEIN; POSTMENOPAUSE; VITAMIN D;

EID: 84886852995     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1978     Document Type: Article

References (32)

1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A., Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-25. J Bone Miner Res. 2007; 22 (3): 465-75.
2. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC 3rd, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH 3rd., Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990; 323 (2): 73-9.
3. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M., Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333 (22): 1437-43.
4. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Fracture Intervention Trial Research Group. Lancet. 1996; 348 (9041): 1535-41.
5. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ., Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280 (24): 2077-82.
6. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR., Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282 (7): 637-45.
7. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD., Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282 (14): 1344-52.
8. Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM., Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2012; 97 (6): 1871-80.
9. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF., Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005; 165 (15): 1762-8.
10. Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis GN, Efstathiadou Z, Kita M, Avramidis A., Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. Int J Clin Pract. 2008; 62 (6): 919-24.
11. Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao DS, Miller PD, Woodson GC 3rd, Lindsay R, Binkley N, Wan X, Ruff VA, Janos B, Taylor KA., Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab. 2012; 97 (8): 2799-808.
12. Han SL, Wan SL., Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Int J Clin Pract. 2012; 66 (2): 199-209.
13. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH., Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344 (19): 1434-41.
14. Capriani C, Irani D, Bilezikian JP., Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res. 2012; 27 (12): 2419-28.
15. Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF., Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003; 88 (2): 569-75.
16. Hattersley G, Bilezikian J, Guerriero J, Kumar P, Zanchetta J, Lyttle CR, O'Dea LSL., editors. Endocrine Reviews. Bone anabolic efficacy and safety of BA 058, a novel analog of hPTHrP: results from a phase 2 clinical trial in postmenopausal women with osteoporosis. Presented at: Endo 2012, the Endocrine Society's 94th Annual Meeting and Expo; June 23-26, 2012; Houston, TX.
17. Horwitz MJ, Tedesco MB, Sereika SM, Syed MA, Garcia-Ocana A, Bisello A, Hollis BW, Rosen CJ, Wysolmerski JJ, Dann P, Gundberg C, Stewart AF., Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res. 2005; 20 (10): 1792-803.
18. Horwitz MJ, Tedesco MB, Sereika SM, Prebehala L, Gundberg CM, Hollis BW, Bisello A, Garcia-Ocana A, Carneiro RM, Stewart AF., A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover. J Bone Miner Res. 2011; 26 (9): 2287-97.
19. Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM., Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res. 2000; 15 (8): 1517-25.
20. Horwitz MJ, Tedesco MB, Sereika SM, Garcia-Ocana A, Bisello A, Hollis BW, Gundberg C, Stewart AF., Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study. Osteoporos Int. 2006; 17 (2): 225-30.
21. Horwitz MJ, Tedesco MB, Garcia-Ocana A, Sereika SM, Prebehala L, Bisello A, Hollis BW, Gundberg CM, Stewart AF., Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab. 2010; 95 (3): 1279-87.
22. Henry JG, Mitnick M, Dann PR, Stewart AF., Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans. J Clin Endocrinol Metab. 1997; 82 (3): 900-6.
23. Plotkin H, Gundberg C, Mitnick M, Stewart AF., Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab. 1998; 83 (8): 2786-91.
24. Stewart AF, Mangin M, Wu T, Goumas D, Insogna KL, Burtis WJ, Broadus AE., Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats. J Clin Invest. 1988; 81 (2): 596-600.
25. Everhart-Caye M, Inzucchi SE, Guinness-Henry J, Mitnick MA, Stewart AF., Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans. J Clin Endocrinol Metab. 1996; 81 (1): 199-208.
26. Syed MA, Horwitz MJ, Tedesco MB, Garcia-Ocana A, Wisniewski SR, Stewart AF., Parathyroid hormone-related protein-(1-36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy. J Clin Endocrinol Metab. 2001; 86 (4): 1525-31.
27. Rizzoli R, Greenspan SL, Bone G 3rd, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC 2nd, Kaur A, Peverly CA, Orloff JJ., Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res. 2002; 17 (11): 1988-96.
28. Vogeser M, Kyriatsoulis A, Huber E, Kobold U., Candidate reference method for the quantification of circulating 25-hydroxyvitamin D3 by liquid chromatography-tandem mass spectrometry. Clin Chem. 2004; 50 (8): 1415-7.
29. Hollis BW, Kamerud JQ, Kurkowski A, Beaulieu J, Napoli JL., Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer. Clin Chem. 1996; 42 (4): 586-92.
30. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB., Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005; 20 (6): 962-70.
31. Cosman F, Dawson-Hughes B, Wan X, Krege JH., Changes in vitamin D metabolites during teriparatide teatment. Bone. 2012; 50: 1368-71.
32. Finkelstein JS, Wyland JJ, Lee H, Neer RM., Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010; 95 (4): 1838-45.